Aggressive interactions of tumor cells and NETs via the CXCL8–CXCR2 axis in DLBCL thus have implications for prognostication and targeting NET formation, and this crosstalk represents a new therapeutic target for this challenging disease [278] and other diseases; e.g., the HMGB1/RAGE/CXCL8 axis could be targeted to inhibit glioma progression [279]. This evidence concerns the gene CXCL8 and diffuse large B-cell lymphoma.